Dendritic cells in cancer vaccines

Experimental Hematology

Volumn 29, Issue 11, 2001, Pages 1247-1255

  Brossart, Peter ^b   Wirths, Stefan ^a   Brugger, Wolfram ^a   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department of Hematology Oncology and Immunology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ARTICLE; BIOLOGY; CANCER; CELL MATURATION; CELL STIMULATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG SAFETY; DRUG SCREENING; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EID: 0034754629     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00730-5     Document Type: Review

References (115)

1. The dendritic cell system and its role in immunogenicity
2. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
3. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
4. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
5. Dendritic cells and the control of immunity
6. Origin, maturation and antigen presenting function of dendritic cells
7. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
8. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cyto-kines
9. Immunobiology of dendritic cells
10. Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage
11. + dendritic cells
12. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis
13. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo
14. Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8(-) dendritic cells, but cross-presented to CD8 T cells by CD8(+) dendritic cells
15. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo
16. Development of CD8α-positive dendritic cells from a common myeloid progenitor
17. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
18. Mast cells in innate immunity
19. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor
20. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation
21. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α: II. Functional analysis
22. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo
23. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
24. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
25. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
26. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells
27. Differentiation of human dendritic cells from monocytes in vitro
28. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
29. The role of CD40 ligand in costimulation and T-cell activation
30. Functions of CD40 on B cells, dendritic cells and other cells
31. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
32. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
33. Cutting edge: Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells
34. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
35. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells
36. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
37. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12
38. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12
39. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development
40. High-level IL-12 production by human dendritic cells requires two signals
41. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
42. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells
43. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils
44. Upon dendritic cell (DC) activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site
45. Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties
46. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
47. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
48. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation
49. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells
50. Tumor necrosis factor α and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells
51. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance
52. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran
53. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor
54. Induction of tolerance by IL-10-treated dendritic cells
55. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
56. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
57. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
58. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells
59. Interleukin-10
60. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response
61. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies
62. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors
63. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
64. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
65. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
66. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma
67. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1
68. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
69. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
70. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
71. Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells
72. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
73. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw&1601
74. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
75. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
76. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
77. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters
78. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
79. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
80. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
81. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
82. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
83. Human tumour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines
84. Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells
85. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma
86. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response
87. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells
88. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
89. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
90. Pro-inflammatory cyto-kines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
91. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells
92. flt3 ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions
93. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
94. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
95. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
96. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells
97. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells
98. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells
99. The development, maturation, and turnover rate of mouse spleen dendritic cell populations
100. In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model
101. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines
102. Dendritic cells injected via different routes induce immunity in cancer patients
103. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
104. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
105. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
106. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
107. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
108. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
109. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
110. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
111. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
112. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
113. Evaluation of the modified ELISPOT assay for γ interferon production in cancer patients receiving antitumor vaccines
114. Phenotypic analysis of antigen-specific T lymphocytes
115. Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues